QT time prolongation
Adverse drug events
|Taste sense altered|
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of abarelix and entrectinib. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for abarelix, when combined with entrectinib (100%). We do not expect any change in exposure for entrectinib, when combined with abarelix (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
Entrectinib has a mean oral bioavailability [ F ] of 60%, which is why the maximum plasma levels [Cmax] tend to change with an interaction. The terminal half-life [ t12 ] is 20 hours and constant plasma levels [ Css ] are reached after approximately 80 hours. The protein binding [ Pb ] is very strong at 99%. The metabolism mainly takes place via CYP3A4.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither abarelix nor entrectinib increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither abarelix nor entrectinib increase anticholinergic activity.
QT time prolongation
Rating: In combination, abarelix and entrectinib can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||aba||ent|
|Taste sense altered||44.0 %||n.a.||44.0|
|Elevated AST||42.0 %||n.a.||42.0|
|Peripheral edema||40.0 %||n.a.||40.0|
|Elevated ALT||36.0 %||n.a.||36.0|
Myalgia (28%): entrectinib
Arthralgia (21%): entrectinib
Fracture (5%): entrectinib
Impaired cognition (27%): entrectinib
Insomnia (14%): entrectinib
Weight gain (25%): entrectinib
Hyperuricemia (9%): entrectinib
Vomiting (24%): entrectinib
Cough (24%): entrectinib
Blurred vision (21%): entrectinib
Fever (21%): entrectinib
Heart failure (3.4%): entrectinib
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.